Abstract
Background This trial is to evaluate the effects of supplementation of Aureobasidium pullulans-N-163 strain produced 1,3-1,-6 beta glucan in young patients with Duchenne muscular dystrophy (DMD).
Methods Twenty-seven male subjects aged 5-19 years with DMD were included, nine in the control arm and 18 in the treatment arm to receive N-163 beta glucan along with conventional therapies for 45 days. While performing the analysis, patients were stratified into: those not administered steroids (Steroid -ve) (Control, n=5; treatment, n=9), those administered steroids (Steroid +ve) (Control, n=4; treatment, n=9), which was not pre-specified.
Results IL-6 showed a significant decrease in the N-163 Steroid -ve group, from 7.2 ± 1.2 pg/ml to ± 0.03 pg/ml. IL-13 decreased in both treatment groups—from 157.76 ± 148.68 pg/ml to 114.08 ± 81.5 pg/ml (N-163 Steroid -ve) and from 289.56 ± 232.88 pg/ml to 255.56 ± 214.13 pg/ml (N-163 Steroid +ve). TGF-β levels showed a significant decrease in the N-163 Steroid –ve group. Dystrophin levels increased by up to 32% in both treatment groups. Medical research council (MRC) grading showed slight improvement in muscle strength improvement in 12 out of 18 patients (67%) in the treatment group and four out of nine (44%) subjects in the control group.
Conclusion Supplementation with the N-163 beta glucan food supplement produced beneficial effects: a significant decrease in inflammation and fibrosis markers, increase in serum dystrophin and slight improvement in muscle strength in DMD subjects over 45 days, thus making this a potential adjunct treatment for DMD after validation.
Trial registration The study was registered in Clinical trials registry of India, CTRI/2021/05/033346. Registered on 5th May, 2021.
Competing Interest Statement
Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the Beta Glucans described in the study.
Clinical Trial
Clinical trials registry of India, CTRI/2021/05/033346
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Ethics Committee (IEC) of Saravana Multispeciality Hospital, India on 12th April, 2021.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
drkraghavan{at}nichimail.jp drddp{at}nichimail.jp masala76{at}gmail.com pushkala66m{at}gmail.com drsudhakar77{at}gmail.com nikewaki{at}phoenix.ac.jp miwasaki{at}yamanashi.ac.jp rsk{at}nichimail.jp drspp{at}nichimail.jp drsam{at}nichimail.jp)
The results have been presented with more clarity
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- DMD
- Duchenne muscular dystrophy
- CK
- Creatinine kinase
- TNF-α
- tumour necrosis factor – Alpha
- MRC
- Medical research council
- NLR
- Neutrophil-to-lymphocyte ratio
- LCR
- Lymphocyte-to-CRP ratio
- LeCR
- Leukocyte-to-CRP ratio
- NASH
- Non-alcoholic steatohepatitis
- 6MWT
- Six-minute walk test
- NSAA
- North Star Ambulatory Assessment
- LGMD
- Limb girdle muscular dystrophy
